Stock Events

Stock Events

Arcturus Therapeutics 

$15.30
160
-$0.26-1.67% 10:28 Today

Statistics

Day High
15.56
Day Low
15.51
52W High
24.17
52W Low
5.5
Volume
37,166
Avg. Volume
-
Mkt Cap
442.26M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.18
-0.9
-0.62
-0.34
Expected EPS
-0.678732
Actual EPS
N/A

Financials

-80.19%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
82.03MRevenue
-65.78MNet Income

Analyst Ratings

24.50Average Price Target
The highest estimate is 27.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ARCT. It's not an investment recommendation.
NVIDIA
31
NVDA
Microsoft
29
MSFT
Tesla
29
TSLA
Apple
28
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap55.09B
Moderna is a leader in mRNA technology, directly competing with Arcturus in the development of mRNA-based vaccines and therapies.
BioNTech
BNTX
Mkt Cap25.64B
BioNTech competes in the mRNA space, particularly in COVID-19 vaccines, similar to Arcturus' efforts in vaccine development.
Pfizer
PFE
Mkt Cap159.36B
Pfizer, in collaboration with BioNTech, is a key player in mRNA vaccine technology, making it a competitor in the same field as Arcturus.
Novavax
NVAX
Mkt Cap1.53B
Novavax competes in the development of vaccines, including COVID-19, which is a focus area for Arcturus Therapeutics.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals focuses on RNAi therapeutics, competing with Arcturus in the broader RNA-based treatment market.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, making it a competitor in the RNA space.
Telesis Bio
TBIO
Mkt Cap17,758
Translate Bio, acquired by Sanofi, focuses on mRNA therapies, directly competing with Arcturus in mRNA technology.
Sarepta Therapeutics
SRPT
Mkt Cap2.2B
Sarepta Therapeutics is involved in RNA-targeted drug development, including therapies for rare diseases, competing with Arcturus' RNA-based approaches.

About

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
Show more...
CEO
Joseph E. Payne
Employees
111
Country
Israel
ISIN
US03969T1097

Listings

XNAS
US
ARCT
BOATS
BOATS
ARCT.BOATS

0 Comments

Share your thoughts

FAQ

What is Arcturus Therapeutics stock price today?▼
The current price of ARCT is $15.30 USD — it has decreased by -1.67% in the past 24 hours. Watch Arcturus Therapeutics stock price performance more closely on the chart.
What is Arcturus Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Arcturus Therapeutics stocks are traded under the ticker ARCT.
Is Arcturus Therapeutics stock price growing?▼
ARCT stock has risen by +2.44% compared to the previous week, the month change is a +150.16% rise, over the last year Arcturus Therapeutics has showed a -7.16% decrease.
What is Arcturus Therapeutics market cap?▼
Today Arcturus Therapeutics has the market capitalization of 442.26M
When is the next Arcturus Therapeutics earnings date?▼
Arcturus Therapeutics is going to release the next earnings report on November 11, 2026.
What were Arcturus Therapeutics earnings last quarter?▼
ARCT earnings for the last quarter are -0.84 USD per share, whereas the estimation was -1 USD resulting in a +15.7% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Arcturus Therapeutics revenue for the last year?▼
Arcturus Therapeutics revenue for the last year amounts to 82.03M USD.
What is Arcturus Therapeutics net income for the last year?▼
ARCT net income for the last year is -65.78M USD.
How many employees does Arcturus Therapeutics have?▼
As of September 04, 2026, the company has 111 employees.
In which sector is Arcturus Therapeutics located?▼
Arcturus Therapeutics operates in the Health & Wellness sector.
When did Arcturus Therapeutics complete a stock split?▼
Arcturus Therapeutics has not had any recent stock splits.
Where is Arcturus Therapeutics headquartered?▼
Arcturus Therapeutics is headquartered in SAN DIEGO, Israel.